Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tenofovir Alafenamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.50 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenofovir Alafenamide SCHEMBL16280324 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL16402708 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL20456396 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL14440384 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL13155662 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL3107144 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL20456397 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL19467840 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL22139335 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 | |
| Tenofovir Alafenamide SCHEMBL13964717 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200407382-A1 | POLYMORPHIC FORMS OF (9-[(R)-2-[[(S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]PHENOXY PHOSPHINYL]METHOXY]PROPYL] ADENINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CIPLA LIMITED (IN) | 2020-12-31 | — | — | US | claimed |
| US-10479810-B2 | Crystal form of tenofovir alafenamide salt, preparation method and use thereof | SHANGHAI BEGREAT PHARMATECH (CN) | 2019-11-19 | — | — | US | claimed |
| US-20190100542-A1 | CRYSTAL FORM OF TENOFOVIR ALAFENAMIDE SALT, PREPARATION METHOD AND USE THEREOF | SHANGHAI BEGREAT PHARMATECH (CN) | 2019-04-04 | — | — | US | claimed |
| EP-2764002-B1 | METHODS FOR PREPARING ANTI-VIRAL NUCLEOTIDE ANALOGS | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | claimed |
| US-9676803-B2 | Efficient process for separation of diastereomers of 9-[(R)-2-[[(R,S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine | CIPLA LIMITED (IN) | 2017-06-13 | — | — | US | claimed |
| US-20160122373-A1 | AN EFFICIENT PROCESS FOR SEPARATION OF DIASTEREOMERS OF 9-[(R)-2-[[(R,S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]-PHENOXYPHOSPHINYL] METHOXY]PROPYL]ADENINE | CIPLA LIMITED (IN) | 2016-05-05 | — | — | US | claimed |
| EP-3004121-A1 | AN EFFICIENT PROCESS FOR SEPARATION OF DIASTEREOMERS OF 9-[(R)-2-[[(R,S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]-PHENOXYPHOSPHINYL]METHOXY]PROPYL]ADENINE | Cipla Limited (IN) | 2016-04-13 | — | — | EP | claimed |
| WO-2014195724-A1 | AN EFFICIENT PROCESS FOR SEPARATION OF DIASTEREOMERS OF 9-[(R)-2-[[(R,S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]-PHENOXYPHOSPHINYL] METHOXY]PROPYL]ADENINE | CIPLA LIMITED (IN) | 2014-12-11 | — | — | WO | claimed |
| US-8664386-B2 | Methods for preparing anti-viral nucleotide analogs | GILEAD SCIENCES, INC. (US) | 2014-03-04 | — | — | US | claimed |
| US-20130090473-A1 | Methods for preparing anti-viral nucleotide analogs | GILEAD SCIENCES, INC. | 2013-04-11 | — | — | US | claimed |
| US-20050124584-A1 | Prodrugs of phosphonate nucleotide analogues | BECKER MARK W (US) | 2005-06-09 | — | — | US | claimed |
| US-20260137623-A1 | Pharmaceutical Formulations Comprising Tenofovir Alafenamide And Emtricitabine | GILEAD SCIENCES INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137622-A1 | PHARMACEUTICAL FORMULATIONS | GILEAD SCIENCES INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12629338-B1 | Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine | GILEAD SCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3852761-B1 | AN ADMINISTRATION REGIMEN OF INTEGRASE INHIBITORS FOR PREVENTING HIV INFECTION BY POST-EXPOSURE PROPHYLAXIS | GILEAD SCIENCES INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20040224917-A1 | Administering combination of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester fumarate (tenofovir disoproxil fumarate) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | GILEAD SCIENCES, INC. | 2004-11-11 | — | — | US | disclosed |
| US-20040224916-A1 | Administering combination comprising 9-[R-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine (GS-7340) or a physiologically functional derivative thereof, and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | GILEAD SCIENCES, INC. | 2004-11-11 | — | — | US | disclosed |
| US-20040018150-A1 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same | BECKER MARK W (US) | 2004-01-29 | — | — | US | disclosed |
| US-20030219727-A1 | Prodrugs of phosphonate nucleotide analogues | BECKER MARK W (US) | 2003-11-27 | — | — | US | disclosed |
| US-20020119443-A1 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same | GILEAD SCIENCES, INC. | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224916-A1 | Administering combination comprising 9-[R-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine (GS-7340) or a physiologically functional derivative thereof, and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | MTAP, TYMP, TYMS | FAP 1649/4885CYP3A4 337/4885CYP2D6 1163/4885 |
| US-20040224917-A1 | Administering combination of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester fumarate (tenofovir disoproxil fumarate) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | DCTD, MTAP, TYMP | FAP 291/4885CYP3A4 471/4885CYP2D6 545/4885 |
| US-20190100542-A1 | CRYSTAL FORM OF TENOFOVIR ALAFENAMIDE SALT, PREPARATION METHOD AND USE THEREOF | MTAP, PNP, HPRT1 | FAP 398/4885CYP3A4 201/4885CYP2D6 206/4885 |
| US-12629338-B1 | Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine | CD4, ACIN1, SAMHD1 | FAP 1846/4885CYP3A4 299/4885CYP2D6 1976/4885 |
| US-20130090473-A1 | Methods for preparing anti-viral nucleotide analogs | MTAP, ADAR, PNP | FAP 1179/4885CYP3A4 2676/4885CYP2D6 2899/4885 |
| US-20260137622-A1 | PHARMACEUTICAL FORMULATIONS | SLC5A1, SI, CD4 | FAP 2075/4885CYP3A4 388/4885CYP2D6 472/4885 |
| US-10479810-B2 | Crystal form of tenofovir alafenamide salt, preparation method and use thereof | MTAP, PNP, HPRT1 | FAP 398/4885CYP3A4 201/4885CYP2D6 206/4885 |
| US-20050124584-A1 | Prodrugs of phosphonate nucleotide analogues | PNP, TYMP, APRT | FAP 1039/4885CYP3A4 1105/4885CYP2D6 1141/4885 |
| US-20200407382-A1 | POLYMORPHIC FORMS OF (9-[(R)-2-[[(S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]PHENOXY PHOSPHINYL]METHOXY]PROPYL] ADENINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MTAP, TYMP, HPRT1 | FAP 691/4885CYP3A4 503/4885CYP2D6 113/4885 |
| US-20040018150-A1 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same | PNP, PNPO, MTAP | FAP 675/4885CYP3A4 886/4885CYP2D6 566/4885 |
| US-20160122373-A1 | AN EFFICIENT PROCESS FOR SEPARATION OF DIASTEREOMERS OF 9-[(R)-2-[[(R,S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]-PHENOXYPHOSPHINYL] METHOXY]PROPYL]ADENINE | MTAP, PARP9, APRT | FAP 1817/4885CYP3A4 758/4885CYP2D6 775/4885 |
| US-20260137623-A1 | Pharmaceutical Formulations Comprising Tenofovir Alafenamide And Emtricitabine | ACIN1, SLC5A1, TPMT | FAP 1960/4885CYP3A4 131/4885CYP2D6 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.